Evidence map›Paper›PMID 40051658›Full record

ArticleNeuro-oncology advances

Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survival.

Eduardo Rodriguez Almaraz, Geno A Guerra, Nadeem N Al-Adli, Jacob S Young, Abraham Dada, Daniel Quintana, Jennie W Taylor, Nancy Ann Oberheim Bush, Jennifer L Clarke, Nicholas A Butowski and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Eduardo Rodriguez AlmarazDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-0978-1117
Geno A GuerraDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-9870-9998
Nadeem N Al-AdliDepartment of Neurological Surgery, University of California, San Francisco, California, USA.
Jacob S YoungDepartment of Neurological Surgery, University of California, San Francisco, California, USA.
Abraham DadaDepartment of Neurological Surgery, University of California, San Francisco, California, USA.
Daniel QuintanaDepartment of Neurological Surgery, University of California, San Francisco, California, USA.
Jennie W TaylorDepartment of Neurology, University of California, San Francisco, California, USA.
Nancy Ann Oberheim BushDepartment of Neurology, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-8302-5008
Jennifer L ClarkeDepartment of Neurology, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-8054-7342
Nicholas A ButowskiDivision of Neuro-Oncology, Department of Neurological Surgery, University of California, San Francisco, California, USA.
John de GrootDivision of Neuro-Oncology, Department of Neurological Surgery, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-1454-6461
Melike PekmezciDepartment of Pathology, University of California, San Francisco, California, USA.
Arie PerryDepartment of Pathology, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-8300-7261
Andrew W BollenDepartment of Pathology, University of California, San Francisco, California, USA.
Aaron W SchefflerDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
David V GliddenDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Joanna J PhillipsDepartment of Pathology, University of California, San Francisco, California, USA.
Joseph F CostelloDepartment of Neurological Surgery, University of California, San Francisco, California, USA.
Edward F ChangDepartment of Neurological Surgery, University of California, San Francisco, California, USA.
Shawn Hervey-JumperDepartment of Neurological Surgery, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-4699-260X
Mitchel S BergerDepartment of Neurological Surgery, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-1983-4892
Stephen S FrancisDepartment of Neurological Surgery, University of California, San Francisco, California, USA.
Susan M ChangDivision of Neuro-Oncology, Department of Neurological Surgery, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-3521-364X
David A SolomonDepartment of Pathology, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-4571-7999

Funding

Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4M
3-D spatial approach to discover genomic effectors of immunosuppression during malignant transformationR01CA244838 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COSTELLO, JOSEPH F · 2020 to 2024
$2.7M
NCI NIH HHS P50 CA097257NCI NIH HHS R01 CA244838
6 · The paper itself

Abstract

Background: Isocitrate dehydrogenase (IDH)-mutant astrocytomas represent the most frequent primary intraparenchymal brain tumor in young adults, which typically arise as low-grade neoplasms that often progress and transform to higher grade despite current therapeutic approaches. However, the genetic alterations underlying high-grade transformation and disease progression of IDH-mutant astrocytomas remain inadequately defined. Methods: Genomic profiling was performed on 205 IDH-mutant astrocytomas from 172 patients from both initial treatment-naive and recurrent post-treatment tumor specimens. Molecular findings were integrated with clinical outcomes and pathologic features to define the associations of novel genetic alterations in the RAS-MAPK signaling pathway. Results: Likely oncogenic alterations within the RAS-MAPK mitogenic signaling pathway were identified in 13% of IDH-mutant astrocytomas, which involved the Conclusions: These findings highlight novel genetic perturbations in the RAS-MAPK pathway as a likely mechanism contributing to the high-grade transformation and treatment resistance of IDH-mutant astrocytomas that may be a potential therapeutic target for affected patients and used for future risk stratification.

Indexed as

astrocytomagliomaIDH1 mutationmolecular neuropathologyRAS-MAPK signaling pathway

Identifiers

PMID40051658
PMCPMC11883348

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.